Stereotactic Body Radiotherapy for Prostate Cancer

Recruiting in Palo Alto (17 mi)

Overseen ByRobert Meier, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Swedish Medical Center

No Placebo Group

Trial Summary

What is the purpose of this trial?The purpose of this study is to find out the effects (good and bad) of highly focused radiation on you and your prostate cancer. The purpose of this evaluation is to see if this treatment causes fewer side effects that other standard treatment approaches, and to evaluate the effect of this treatment on your prostate tumor and your quality of life over time.

Eligibility Criteria

Men with prostate cancer can join this trial if they have a confirmed diagnosis, are in good physical condition (Karnofsky score of 70-100), and fall into one of three risk groups based on tumor size, Gleason score, and PSA levels. Hormone therapy is allowed under specific conditions for each risk group.

Inclusion Criteria

My cancer is in an early to mid-stage and may or may not have spread to nearby lymph nodes.

My prostate cancer is classified as low, intermediate, or high risk.

I am mostly able to care for myself and carry out normal activities.

My prostate cancer was confirmed through a tissue examination.

Participant Groups

The trial is testing the effects of CyberKnife Stereotactic Radiosurgery—a type of highly focused radiation—on prostate tumors. It aims to see if this method has fewer side effects than standard treatments and how it impacts patients' quality of life over time.

1Treatment groups

Experimental Treatment

Group I: CyberKnife Stereotactic RadiosurgeryExperimental Treatment1 Intervention

This treatment concentrates large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. CyberKnife Stereotactic Radiosurgery is not investigational and is considered standard of care.